{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:41:03Z","timestamp":1762674063968},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,10,3]],"date-time":"2015-10-03T00:00:00Z","timestamp":1443830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s12020-015-0748-x","type":"journal-article","created":{"date-parts":[[2015,10,3]],"date-time":"2015-10-03T08:17:16Z","timestamp":1443860236000},"page":"222-224","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Duration of anti-resorptive therapy for osteoporosis"],"prefix":"10.1007","volume":"51","author":[{"given":"Robert A.","family":"Adler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,3]]},"reference":[{"key":"748_CR1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/gerona\/glt092","volume":"68","author":"KE Ensrud","year":"2013","unstructured":"K.E. Ensrud, Epidemiology of fracture risk with advanced age. J. Gerontol. A 68, 1236\u20131242 (2013)","journal-title":"J. Gerontol. A"},{"key":"748_CR2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King, A. Tosteson, Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J. Bone Miner. Res. 22, 465\u2013475 (2007)","journal-title":"J. Bone Miner. Res."},{"key":"748_CR3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","volume":"18","author":"CJ Crandall","year":"2014","unstructured":"C.J. Crandall, S.J. Newberry, A. Diamant, Y.W. Lim, W.F. Gellad, M.J. Booth, A. Motala, P.G. Shekelle, Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann. Intern. Med. 18, 711\u2013723 (2014)","journal-title":"Ann. Intern. Med."},{"issue":"Suppl 2","key":"748_CR4","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1007\/s00198-010-1253-y","volume":"21","author":"JA Kanis","year":"2010","unstructured":"J.A. Kanis, E.V. McCloskey, H. Johansson, A. Oden, O. Strom, F. Borgstrom, Development and use of FRAX in osteoporosis. Osteoporos. Int. 21(Suppl 2), S407\u2013S413 (2010)","journal-title":"Osteoporos. Int."},{"key":"748_CR5","author":"AC Abraham","year":"2015","unstructured":"A.C. Abraham, A. Agarwalla, A. Yadavalli, C. McAndrew, J.Y. Liu, S.Y. Tang, Multiscale predictors of femoral neck in situ strength in aging women: contributions of BMD, cortical porosity, reference point indentation, and nonenzymatic glycation. J. Bone Miner. Res. (2015). doi: 10.1002\/jbmr.2568","journal-title":"J. Bone Miner. Res."},{"key":"748_CR6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","volume":"154","author":"United States Preventive Services Task Force","year":"2011","unstructured":"United States Preventive Services Task Force, Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann. Intern. Med. 154, 356\u2013364 (2011)","journal-title":"Ann. Intern. Med."},{"key":"748_CR7","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","volume":"25","author":"ES Siris","year":"2014","unstructured":"E.S. Siris, R. Adler, J. Bilezikian, M. Bolognese, B. Dawson-Hughes, M.J. Favus, S.T. Harris, S.M. Jan de Beur, S. Khosla, N.E. Lane, R. Lindsay, A.D. Nana, E.S. Orwoll, K. Saag, S. Silverman, N.B. Watts, The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos. Int. 25, 1439\u20131443 (2014)","journal-title":"Osteoporos. Int."},{"key":"748_CR8","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"D.M. Black, A.V. Schwartz, K.E. Ensrud, J.A. Cauley, S. Levis, S.A. Quandt, S. Satterfield, R.B. Wallace, D.C. Bauer, L. Palermo, L.E. Wehren, A. Lombardi, A.C. Santora, S.R. Cummings, FLEX Research Group: effects of continuing or stopping alendronate after 5\u00a0years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296, 2927\u20132938 (2006)","journal-title":"JAMA"},{"key":"748_CR9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"D.M. Black, I.R. Reid, S. Boonen, C. Bucci-Rechtweg, J.A. Cauley, F. Cosman, S.R. Cummings, T.F. Hue, K. Lippuner, P. Lakatos, P.C. Leung, Z. Man, R.L. Martinez, M. Tan, M.E. Ruzycky, G. Su, R. Eastell, The effect of 3 versus 6\u00a0years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON Pivotal Fracture Trial (PFT). J. Bone Miner. Res. 27, 243\u2013254 (2012)","journal-title":"J. Bone Miner. Res."},{"key":"748_CR10","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","volume":"366","author":"DM Black","year":"2012","unstructured":"D.M. Black, D.C. Bauer, A.V. Schwartz, S.R. Cummings, C.J. Rosen, Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long? N. Engl. J. Med. 366, 2051\u20132053 (2012)","journal-title":"N. Engl. J. Med."},{"key":"748_CR11","author":"RA Adler","year":"2015","unstructured":"R.A. Adler, G. El-Hajj Fuleihan, D.C. Bauer, P.M. Camacho, B.L. Clarke, G.A. Clines, J.E. Compston, M.T. Drake, B.J. Edwards, M.J. Favus, S.L. Greenspan, R. McKinney Jr., R.J. Pignolo, D.E. Sellmeyer, Managing osteoporosis patients after long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. (2015). doi: 10.1002\/jbmr.2708","journal-title":"J. Bone Miner. Res."},{"key":"748_CR12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","volume":"50","author":"A Grey","year":"2012","unstructured":"A. Grey, M.J. Bolland, A. Horne, D. Wattie, M. House, G. Gamble, I.R. Reid, Five years of anti-resorptive activity after a single dose of zoledronate: results from a randomized double-blind placebo-controlled trial. Bone 50, 1389\u20131393 (2012)","journal-title":"Bone"},{"key":"748_CR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"A.A. Khan, A. Morrison, D.A. Hanley, D. Felsenberg, L.K. McCauley, F. O\u2019Ryan, I.R. Reid, S.L. Ruggiero, A. Taguchi, S. Tetradis, N.B. Watts, M.L. Brandi, E. Peters, T. Guise, R. Eastell, A.M. Cheung, S.N. Morin, B. Masri, C. Cooper, S.L. Morgan, B. Overmayer-Pietsch, B.L. Langdahl, R. Al Dabagh, K.S. Davison, D.L. Kendler, G.K. Sanders, J.P. Brown, J. Compston, International task force on osteonecrosis of the jaw: diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res. 30, 3\u201323 (2015)","journal-title":"J. Bone Miner. Res."},{"key":"748_CR14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJMc1403799","volume":"371","author":"J Schilcher","year":"2014","unstructured":"J. Schilcher, V. Koeppen, P. Aspenberg, K. Michaelsson, Risk of atypical femoral fracture during and after bisphosphonate use. N. Engl. J. Med. 371, 974\u2013976 (2014)","journal-title":"N. Engl. J. Med."},{"key":"748_CR15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/RHU.0000000000000170","volume":"20","author":"MM Safford","year":"2014","unstructured":"M.M. Safford, A. Barasch, J.R. Curtis, R. Outman, K. Saag, Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration. J. Clin. Rheumatol. 20, 357\u2013362 (2014)","journal-title":"J. Clin. Rheumatol."},{"key":"748_CR16","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2106\/JBJS.N.00075","volume":"96","author":"JE Hagen","year":"2014","unstructured":"J.E. Hagen, A.N. Miller, S.M. Ott, M. Gardner, S. Morshed, K. Jeray, T.B. Alton, D. Ren, W.P. Abblitt, J.C. Krieg, Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. J. Bone Joint Surg. Am. 96, 1905\u20131909 (2014)","journal-title":"J. Bone Joint Surg. Am."},{"key":"748_CR17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00776-014-0572-9","volume":"19","author":"Y Oh","year":"2014","unstructured":"Y. Oh, Y. Wakabayashi, Y. Kurosa, M. Ishizuki, A. Okawa, Stress fracture of the bowed femoral shaft is another cause of atypical femoral fracture in elderly Japanese: a case series. J. Orthop. Sci. 19, 579\u2013586 (2014)","journal-title":"J. Orthop. Sci."},{"key":"748_CR18","first-page":"e206","volume":"21","author":"JC Lo","year":"2015","unstructured":"J.C. Lo, S. Srinivasan, M. Chandra, M. Patton, A. Budayr, L.H. Liu, G. Lau, C.D. Grimsrud, Trends in mortality following hip fracture in older women. Am. J. Manag. Care 21, e206\u2013e214 (2015)","journal-title":"Am. J. Manag. Care"},{"key":"748_CR19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"K.W. Lyles, C.S. Colon-Emeric, J.S. Magaziner, J.D. Adachi, C.F. Pieper, C. Mautalen, \u2013: Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357, 1799\u20131809 (2007)","journal-title":"N. Engl. J. Med."},{"key":"748_CR20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/jc.2010-2730","volume":"96","author":"JR Center","year":"2011","unstructured":"J.R. Center, D. Bliuc, N.D. Nguyen, T.V. Nguyen, J.A. Eisman, Osteoporosis medication and reduced mortality risk in elderly women and men. J. Clin. Endocrinol. Metab. 96, 1006\u20131014 (2011)","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0748-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-015-0748-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0748-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T05:05:46Z","timestamp":1599627946000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-015-0748-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s12020-015-0748-x","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,3]]}}}